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suggesting that other factors, such as local immunity or
coinfections, may play an important role in viral shedding.
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Background: Infection of HIV-1 can result in a variety of
central nervous system syndromes. Neurons are damaged
through several indirect means. Cytotoxic T-lymphocytes
play important role among other immune processes. The
mechanism of CTL dysfunction as associated with HAD has
not been elucidated. Down-regulation of CD127 on CTL has
been implicated in different situations.
Methodology: Women HIV+ individuals with dementia
(score 7.5) were included. Age matched healthy volunteers
taken as normal control (NC, n = 4). Phenotypic analysis of
peripheral blood cells included for CD4, CD8, CD127, CD45RA
and CD45RO markers on the surface. The percent of CTL
expressing intracellular perforin and granzyme B was evalu-
ated by multicolour ﬂowcytometery. IFN  was estimated by
ELISpot assay and plasma IL-7 levels by ELISA. The statistical
analysis done using PRISM software and two-tailed student’s
‘t’-test.
Results: The mean CD4 count in HAD group with 269
cells/L, and viral load 19095 copies/ml, it was 485 cells/L
and 7527 copies/ml respectively in HIV-ND patients. The
frequency of CD4+CD127+ cells was 9.8% in HAD group
as compared to 17.04% in HIV-ND group and 32.18% in
NC subjects. The percent of CD127 expressing CD8+ cells
was 14.34% in HAD as compared to 18.67% in HIV-ND and
16.65% in NC. CD8+ cells expressing intracellular Granzyme
B and Perforin were 59.4 + 20.9 and 34.05 + 19.09 in HAD
patients as compared to HIV-ND patients (47.5 + 19.55 and
26.94 + 16.17). There was an increase in terminally differen-
tiated effector cells in HAD patients as compared to HIV-ND
patients. A signiﬁcant correlation was found between the
dementia score and the frequency of CD8+ cells expressing
Granzyme B.
Conclusions: The ﬁndings indicate an expansion of acti-
vated CD8+ effector cell subpopulation in the chronically
infected HIV patients with prolonged periods of disease, may
be responsible for enhanced killing of neuronal cells leading
to dementia.
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Background: Human immunodeﬁciency virus Gag is a
highly conserved dominant antigen which induces both
humoral and cellular immune responses during natural infec-
tion. It is a good target for use in serodiagnostics or
vaccine development. However, when Gag is overexpressed
in Escherichia coli, it is highly insoluble and forms protein
aggregates called inclusion bodies. This makes puriﬁcation
of the antigen very difﬁcult. The objective of the current
study was to purify HIV-1 subtype C Gag expressed as inclu-
sion bodies from E. coli for possible use in enzyme-linked
immunosorbent assays.
Methods: A codon-optimized gag gene was cloned into an
expression plasmid which contained a hexa-histidine puriﬁ-
cation tag. The plasmid was used to generate a recombinant
E. coli expressing Gag. The expression of the Gag was
analyzed by SDS-PAGE and Western blotting. The Gag was
puriﬁed from the bacteria using the QIA-Express Fast Start
Ni + NTA kit (QIAGEN, Germany) under denaturing conditions
and conﬁrmed by SDS-PAGE and Western blotting. The puri-
ﬁed Gag was used as a capturing antigen in ELISA tests to
determine the presence of Gag antibodies in sera of an HIV-
positive patient or guinea pigs immunized with a vaccine
expressing Gag-Tat-Nef-RT.
Results: High levels of HIV Gag were expressed in the E.
coli bacteria, but mainly as inclusion bodies. The antigen
was successfully puriﬁed from the inclusion bodies follow-
ing solubilization and its antigenicity was demonstrated by
Western blotting. An ELISA test showed the presence of
Gag antibodies in serum of an HIV-seropositive patient. The
absorbance was 12-times above the background. The ELISA
test further showed that Gag antibodies in sera of HIV
DNA/MVA-vaccinated guinea pigs could be detected.
Conclusion: HIV-1 subtype C Gag expressed in E. coli can
be puriﬁed and used in ELISA tests in diagnostics or vaccine
research.
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Nowadays, there are various HIV-1 subtyping techniques,
among them full-length sequencing is the most accurate
technique to characterize HIV viral genomes and that will
reveal the subtype and any recombinant structure of the
genome. Although sequencing remains the most informative
method, it is technically challenging, time consuming and
expensive for use as a screening tool for large-scale surveil-
lance, especially in developing countries. To circumvent this
problem, easier and faster techniques are needed for rou-
tine subtyping. One of the techniques the Heteroduplex
Mobility Assay (HMA) has been introduced by UNAIDS in sev-
eral developing countries as a tool for monitoring subtypes
distribution. HMA has also been used to rapidly characterize
HIV-1 strains as part of the WHO sponsored vaccine evalua-
tion programmed to identify subtypes and to investigate the
heterogeneity of strains in the different parts of the world
including South East Asia (SEA) countries such as Thailand,
etc. In my study, the Heteroduplex Mobility Assay (HMA) was
started to utilize for the ﬁrst time in Myanmar to determine
